title: Drug repurposing for gastrointestinal stromal tumor.
abstract: Despite significant treatment advances over the past decade, metastatic gastrointestinal stromal tumor (GIST) remains largely incurable. Rare diseases, such as GIST, individually affect small groups of patients but collectively are estimated to affect 25 to 30 million people in the United States alone. Given the costs associated with the discovery, development, and registration of new drugs, orphan diseases such as GIST are often not pursued by mainstream pharmaceutical companies. As a result, "drug repurposing" or "repositioning," has emerged as an alternative to the traditional drug development process. In this study, we screened 796 U.S. Food and Drug Administration (FDA)-approved drugs and found that two of these compounds, auranofin (Ridaura) and fludarabine phosphate, effectively and selectively inhibited the proliferation of GISTs, including imatinib-resistant cells. One of the most notable drug hits, auranofin, an oral, gold-containing agent approved by the FDA in 1985 for the treatment of rheumatoid arthritis, was found to inhibit thioredoxin reductase activity and induce reactive oxygen species (ROS) production, leading to dramatic inhibition of GIST cell growth and viability. Importantly, the anticancer activity associated with auranofin was independent of imatinib-resistant status, but was closely related to the endogenous and inducible levels of ROS. Coupled with the fact that auranofin has an established safety profile in patients, these findings suggest for the first time that auranofin may have clinical benefit for patients with GIST, particularly in those suffering from imatinib-resistant and recurrent forms of this disease.
authors: Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA.
authors: Ziyan Y
authors: ZY
authors: Pessetto
authors: Scott J
authors: SJ
authors: Weir
authors: Geetika
authors: G
authors: Sethi
authors: Melinda A
authors: MA
authors: Broward
authors: Andrew K
authors: AK
authors: Godwin
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D001310:Auranofin / Q000494:pharmacology*; D018929:Cell Culture Techniques; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D058492:Drug Repositioning; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D001310:Auranofin; D014740:Vidarabine; C024352:fludarabine
references: Arthritis Rheum. 1990 Oct;33(10):1449-61
references: 1977391
references: Oncogene. 2001 Aug 16;20(36):5054-8
references: 11526490
references: Chem Biol. 2007 Oct;14(10):1128-39
references: 17961825
references: Curr Oncol Rep. 2009 Jul;11(4):314-21
references: 19508837
references: Biochem Pharmacol. 1987 Mar 1;36(5):769-72
references: 3493779
references: J Clin Oncol. 2006 Oct 10;24(29):4764-74
references: 16954519
references: Science. 2003 Jan 31;299(5607):708-10
references: 12522257
references: Antioxid Redox Signal. 2006 Mar-Apr;8(3-4):243-70
references: 16677071
references: Free Radic Biol Med. 1995 Apr;18(4):775-94
references: 7750801
references: Cancer. 2010 Nov 15;116(22):5126-37
references: 20661913
references: Gastroenterology. 2010 Sep;139(3):942-52
references: 20621681
references: Science. 1998 Jan 23;279(5350):577-80
references: 9438854
references: Mol Cancer Ther. 2003 Aug;2(8):699-709
references: 12939459
references: Free Radic Res. 2005 Jul;39(7):687-95
references: 16036347
references: Circ Res. 2004 Jun 11;94(11):1483-91
references: 15117824
references: Nat Rev Mol Cell Biol. 2007 Sep;8(9):722-8
references: 17700625
references: Biochem Pharmacol. 1989 Jul 1;38(13):2087-9
references: 2735946
references: Curr Top Med Chem. 2011;11(21):2647-60
references: 22039866
references: Nature. 2007 Aug 9;448(7154):645-6
references: 17687303
references: Biochem Pharmacol. 2010 Jan 15;79(2):90-101
references: 19665452
references: Nat Chem Biol. 2007 Aug;3(8):438-41
references: 17637769
references: Cancer Res. 2012 Mar 1;72(5):1055-8
references: 22246671
references: Cancer Res. 2006 May 15;66(10):5477-86
references: 16707477
references: Cancer Chemother Pharmacol. 2011 Jan;67 Suppl 1:S25-43
references: 21116624
references: Leuk Res. 2011 Feb;35(2):243-9
references: 20542334
references: Pharmacotherapy. 1983 Sep-Oct;3(5):284-98
references: 6417628
references: Pharmazie. 2011 Jun;66(6):440-4
references: 21699084
references: J Clin Oncol. 2005 Aug 20;23(24):5795-804
references: 16110036
references: J Immunol. 2000 Jun 1;164(11):5981-9
references: 10820281
references: Antioxid Redox Signal. 2008 Aug;10(8):1343-74
references: 18522489
references: Free Radic Biol Med. 1998 Jan 15;24(2):370-6
references: 9433913
references: Cancer. 2008 Oct 1;113(7):1532-43
references: 18671247
references: Mol Cancer Ther. 2011 Nov;10(11):2026-7
references: 22072810
references: J Pathol. 2011 Jan;223(2):251-61
references: 21125679
references: Br J Pharmacol. 2005 Oct;146(4):506-13
references: 16086031
references: Virchows Arch B Cell Pathol Incl Mol Pathol. 1985;49(4):385-93
references: 2867637
references: Cancer Res. 2012 Mar 1;72(5):1126-36
references: 22258453
references: Am J Clin Pathol. 2010 Jan;133(1):141-8
references: 20023270
references: Nat Med. 2012 Jun;18(6):956-60
references: 22610278
references: Clin Rheumatol. 1984 Mar;3 Suppl 1:39-50
references: 6432412
references: Nat Rev Cancer. 2011 Nov 17;11(12):865-78
references: 22089421
references: Genes Chromosomes Cancer. 2009 Oct;48(10):886-96
references: 19585585
references: Mol Cancer. 2009 Nov 10;8:99
references: 19903356
references: Biochem Biophys Res Commun. 2003 Apr 25;304(1):119-24
references: 12705894
references: Methods Enzymol. 2010;474:109-22
references: 20609907
references: J Microbiol Biotechnol. 2009 Nov;19(11):1355-63
references: 19996687
references: Annu Rev Pathol. 2008;3:557-86
references: 18039140
references: Circ Res. 1992 Mar;70(3):593-9
references: 1371430
references: Gastroenterology. 2008 Apr;134(4):1083-93
references: 18395089
references: J Rheumatol. 1988 Jan;15(1):28-34
references: 3280795